Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

BIO Statement on Biosimilar User Fee Act Goals Letter

Biotechnology Innovation Organization
Posted on: 17 Sep 16

Biotechnology Innovation Organization (BIO) Senior Vice President for Science Policy Kay Holcombe released the following statement today regarding the Biosimilar User Fee Act (BsUFA) II goals letter:

“BIO and our member companies strongly supported the establishment of a pathway for the approval of biosimilars because we recognized that market entry of safe and effective biosimilars may provide increased choices for patients and physicians. We remain committed to ensuring the success of the emerging biosimilars market through our engagement in ongoing policy developments related to biosimilars, including our recent participation in the technical negotiations for the reauthorization of BsUFA.

“The goals and commitments reflected in the thoughtful and carefully negotiated BsUFA II goals letter will expand and build upon the initial success of BsUFA I by ensuring that the FDA has the resources necessary to review biosimilar biological products in an efficient and timely manner while maintaining the Agency’s high standards for safety and efficacy and by making structural modifications that will enhance the operation of the biosimilars user fee program.

“Among the many enhancements to the biosimilars review process envisioned in the goals letter, we are particularly pleased with the Agency’s commitment to establish a program for enhanced communications during the biosimilars review process. A similar program in PDUFA has been tremendously successful in improving communications between Sponsors and the Agency at key points in the development process, resulting in a more efficient process for sponsors and the FDA alike.

“We also applaud the Agency’s commitment to implement a new time reporting system and to enhance financial transparency, to provide more accurate data on which to base accurate tracking of the use of BsUFA resources and a clear picture of that resource allocation. The commitments to improve FDA recruitment, hiring and retention of staff necessary to accomplish the goals of the biosimilars program are significant and crucial to the program’s success.

“We look forward to working with Congress, the administration, patient and provider groups, and all stakeholders to ensure that BsUFA is reauthorized in a timely manner and that the important enhancements to the program laid out in the goals letter are implemented most effectively.”

About BIO

BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIOtechNOW is BIO's blog chronicling “innovations transforming our world” and the BIO Newsletter is the organization’s bi-weekly email newsletter. Subscribe to the BIO Newsletter.

Upcoming BIO Events


BIO Animal Biotech Summit

September 21-23, 2016

Bethesda, MD

BIO IP & Diagnostics Symposium

September 29, 2016

Alexandria, VA


BIO Investor Forum

October 18-19, 2016

San Francisco, CA

BIO Latin America Conference

October 26-28, 2016
Grand Hyatt São Paulo, Brazil


View source version on

Business Wire

Last updated on: 17/09/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.